Seven of the top ten drugs on the market are biologics. And, an explosion in the number in development pipelines, means demand for manufacturing capacity is still increasing.
As an industry, we have manufacturing capacity, but the question is whether it is the right capacity? The biologics in development today are typically high value, niche drugs. These require the production of larger numbers of smaller batches compared to the previous generation of blockbuster drugs, which are produced in lower numbers of much larger batches.